Medicine
Safety of favipiravir in COVID-19 patients with end stage renal disease
N. A. Shah, S. Sukahri, I. Abidin
tlooto Summary
Despite being a high-risk group, ESRD did not increase overall risk of AE with favipiravir use, and in multivariate analysis, the history of drug allergy was the only significant predictor of AE.
Abstract
Abstract is not available.
Citation format
SHAH, N. A.; SUKAHRI, S.; ABIDIN, I. Safety of favipiravir in COVID-19 patients with end stage renal disease. Medical Journal of Malaysia, 2022, 77(Supplement 3).